Latest Safety News

Brightstar Resources (ASX:BTR) has fully funded its Goldfields Project development with a $193 million equity raise and a US$120 million senior secured bond, targeting 75,000oz gold production from mid-2027 while progressing Sandstone towards a Final Investment Decision.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Ramelius Resources reported solid March quarter gold production with higher costs driven by earlier commercial production at Dalgaranga, rising diesel prices, and increased royalties. The Mt Magnet plant upgrade advances while exploration highlights support future growth.

Carnaby Resources has delivered a robust Pre-Feasibility Study and declared its maiden Ore Reserve at the Greater Duchess Copper Gold Project, setting sights on first production in the second half of 2026.

Image Resources delivered a solid first quarter at its Atlas project with production and sales within guidance, operating costs under forecast, and secured a six-month debt repayment holiday. Development advances on multiple mineral sands projects and maiden gold resource drilling is underway.

Westgold Resources maintained FY26 gold production guidance with 93,145oz in Q3, backed by a record A$7,080/oz gold price and a robust A$285M underlying cash build. The company approved a $145M expansion of its Higginsville processing hub to boost capacity and cut costs.

St Barbara Limited has closed a A$389 million investment deal with Lingbao Gold Group, greenlighting a US$333 million expansion of the New Simberi Gold Project and securing key environmental approvals for its Nova Scotia operations.

Grange Resources delivered a steady first quarter in 2026 with solid production at Savage River, no lost time injuries for nearly three years, and progressing financing for its North Pit Underground project.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Etherstack has smashed its first half revenue record for FY26 with strong government contract deliveries, prompting an upward revision of full-year revenue guidance to as much as US$18.9 million.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.